Nemolizumab achieved the 2 primary endpoints in the phase 3 OLYMPIA 1 study for itch and Investigator’s Global Assessment (IGA) success in prurigo nodularis (PN) after 16 weeks. Statistically significant differences compared with placebo in itch reduction were already evident at week 4.
The mean age of the participants was 57.5 and 58% were women. In this population with moderate-to-severe PN, overall 60% had a baseline IGA of 3 and the mean weekly average itch by PP NRS was 8.5.
At week 16, 58.4% achieved an itch reduction in PP NRS on nemolizumab versus 16.7% on placebo (P<0.0001). “We see a significant separation of both groups with over 40% of patients achieving this endpoint already at week 4, and this means they received only 1 injection of nemolizumab,” Prof. Sonja Ständer (Münster University Hospital, Germany) highlighted.
Furthermore, 26.3% of participants on the study drug achieved IGA 0/1 compared with 7.3% in the placebo arm (P=0.0001). The inter-group differences in IGA success demonstrated significant superiority of nemolizumab as of week 8. Also, the proportion of participants with >75% healed lesions on nemolizumab was already highly significant at week 8 (P≤0.0001) with 47.9% versus 15.6% (P≤0.0001) at week 24. “With the conventional therapies we never saw something like this before in the moderate-to-severe PN population,” Prof. Ständer stated. She further pointed out that nemolizumab was overall well-tolerated.
“These results confirm the results of the OLYMPIA 2 study, the other phase 3 study, and now I hope you can understand why we are so excited,” Prof. Ständer concluded.
- Ständer S. Nemolizumab monotherapy improves itch and skin lesions in patients with moderate-to-severe prurigo nodularis: results from a global phase 3 trial (OLYMPIA 1). 1D, EADV Congress 2023, 11–14 October, Berlin, Germany.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« JAK inhibitor provides sustained skin clearance in adolescents and adults with AD Next Article
Anti-IL17 blockade leads to maintained pain reduction in patients with HS »
« JAK inhibitor provides sustained skin clearance in adolescents and adults with AD Next Article
Anti-IL17 blockade leads to maintained pain reduction in patients with HS »
Table of Contents: EADV 2023
Featured articles
Tapinarof on course to become a new topical treatment in AD
AD and Eczema in 2023
Tapinarof on course to become a new topical treatment in AD
Upadacitinib provides sustained skin clearance in adolescents and adults with AD
Sustained deep clinical and itch responses with novel IL-13 inhibitor
IL-13 inhibitor shows potential in atopic dermatitis
Encouraging results for amlitelimab in atopic dermatitis
Chronic hand eczema: patients share similar molecular signatures regardless of AD status
Severe hand eczema: dupilumab could be a future treatment
Psoriasis News
Dual IL-17 blockade yields efficacy on joints and skin
High-dose subcutaneous spesolimab prevents GPP flares up to week 48
Drug survival of guselkumab and risankizumab seems superior to other biologics
IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis
First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis
Hidradenitis Suppurativa: End of the Diagnostic and Therapeutic Draught
Skin tape stripping allows a novel precision medicine approach in HS
Nanobodies: A novel way to treat HS
Anti-IL17 blockade leads to maintained pain reduction in patients with HS
Vitiligo: Novel Treatment Options
JAK1 inhibition: a promising forthcoming treatment option in vitiligo
Vitiligo: Continuation of topical ruxolitinib successful in many initial non-responders
Alopecia Areata: Novel Developments
JAK3/TEC inhibition achieves clinically meaningful responses in AA
Alopecia areata: remarkable regrowth rates with deuruxolitinib
Botanical drug solution improves hair regrowth in children and adolescents with AA
What’s New in Other Disease Entities
Nemolizumab shows high success rates in prurigo nodularis
Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU
Innovative wound gel reduces frequency of painful dressing changes in epidermolysis bullosa
Best of the Posters
Women with psoriasis face increased adverse effects with systemic therapy
Improved AI tool shows high sensitivity rates in skin cancer detection
Dermoscopy training combined with AI significantly improves skin cancer detection
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com